2024澳门原料网站-免费完整资料
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2020-07-29
Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar
2020-06-24
Cooperation with Accord Upgraded: to Bring High Quality Products to More Patients
2020-06-16
Phase 3 Trial of Henlius Bevacizumab Biosimilar HLX04 in Metastatic Colorectal Cancer Met Study Primary Endpoint
2020-06-05
Exclusive Interview with Henlius Senior Vice President of Manufacturing & Engineering, Mrs Wei Huang
2020-05-31
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
2020-05-27
Henlius Received IND Approval for Denosumab Biosimilar HLX14 from NMPA
2020-04-24
First Patient in Overseas Trial Site Dosed in an International Multi-centre Phase 3 Study of Henlius Anti-PD-1 mAb HLX10 in ES-SCLC
2020-04-23
Henlius Receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
2020-04-23
First Patient in Overseas Trial Site Dosed in the Multi-centre International Phase 3 Study of Henlius Anti-PD-1 mAb for the Treatment of Lung Cancer
1
2
3
4
5